Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

Phase 4

Terminated

• Conditions: Non-Insulin-dependent Diabetes Mellitus
• Interventions: Dietary Supplement: placebo; Dietary Supplement: 3.4 g psyllium BID; Dietary Supplement: 6.8g psyllium BID

• Registration Number: NCT01582282
• Lead Sponsor: Procter and Gamble

Brief Summary

A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2) a 12-week treatment period, at the beginning of which, Subjects are randomly assigned to 1 of the 3 treatment groups: placebo, 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil) or 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil). For 12 weeks, Subjects took Metamucil or the fiber-free placebo BID, just prior to breakfast and dinner.

Patients visited the clinic 10 times during the 20-week period at Screening, Weeks -8, -6, -4, 0, Day 3, and Weeks 2, 4, 8 and 12, fasting at least 12 hours prior to each visit where a blood sample was taken (all visits except Week -6 and Day 3) for analysis of fasting serum glucose and lipid levels, and HbA1c. Clinical chemistry, hematology and urinalysis were done at Weeks -8, 0 and 12. The completed 7-day food diaries were reviewed by the study dietician at each visit and discussed with the patient to ensure compliance with the recommended diet and the patients' body weights were recorded

Detailed Description

During the first phase, lead-in period during Subjects followed a diet judged to be within the acceptable guidelines of the ADA, with compliance assessed by a study dietician using 7-day food diaries completed by the patients. Subject body weight, serum glucose and serum HbA1c, and lipid levels were allowed to stabilize during this period.

During the 12-week treatment period, Subjects were stratified by either diet alone or diet and oral hypoglycemic medication and randomly assigned to 1 of the 3 treatment groups: placebo, 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil) or 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil). For 12 weeks, patients took Metamucil or the fiber-free placebo BID, just prior to breakfast and dinner.

Patients visited the clinic 10 times during the 20-week period at Screening, Weeks -8, -6, -4, 0, Day 3, and Weeks 2, 4, 8 and 12, fasting at least 12 hours prior to each visit where a blood sample was taken (all visits except Week -6 and Day 3) for analysis of fasting serum glucose and lipid levels, and HbA1c. Clinical chemistry, hematology and urinalysis were done at Weeks -8, 0 and 12. The completed 7-day food diaries were reviewed by the study dietician at each visit and discussed with the patient to ensure compliance with the recommended diet and the patients' body weights were recorded.

Study Timeline

• Study Start: 1988-05
• Primary Completion: 1990-01
• Study Completion: 1990-01
• Study First Submitted: 2012-04-18
• Study First Submitted QC: 2012-04-19
• Study First Posted: 2012-04-20
• Results First Submitted: 2012-10-03
• Results First Submitted QC: 2012-10-03
• Status Verified: 2012-11
• Results First Posted: 2012-11-02
• Last Update Submitted: 2012-11-08
• Last Update Posted: 2012-11-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Have a clinical diagnosis of Type II diabetes mellitus, controlled by diet and/or second generation oral hypoglycemic drugs, with the onset of the disease after age 35.
• Are between 0 and 50% above "normal" body weight (adjusted by frame) according to the Metropolitan Life Insurance Tables.
• Are male or female, aged 36-80 years with a diagnosis made at least 1 year prior to enrollment.
• Have an HbA1c level between 6 and 10%
• Have a fasting serum glucose level between 120-220 mg/dL and not vary by more than ±20% during the month prior to entering the treatment phase and HbA1c levels not vary by more than ±10% during the month prior to entering the treatment phase. Serum glucose level must have been between 120-220mg/dl and the subject's HbA1c between 6 and 10% at Week 0.
• Have been on a "stable" diet consistent with ADA-recommended dietary guidelines with intake of total dietary fiber < 15g/1000 calories and were willing to maintain this diet during the 20-week study.
• Have maintained a constant body weight (±5%) during the month prior to entering the treatment phase

Exclusion Criteria

• Have a condition that would interfere with evaluation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	matched placebo BID
psyllium 3.4g BID	3.4 g psyllium BID	3.4g psyllium BID for a Total of 6.8g daily
6.8g psyllium BID	6.8g psyllium BID	6.8g psyllium BID for a total of 13.6 g/day

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Fasting Glucose	12 weeks	Change from Baseline is defined as the Post-Baseline value subtracted from the Baseline value
Change From Baseline in Fasting HbA1c	12 weeks	Change is defined as Post-Baseline minus Baseline
Change From Baseline in Fasting HDL Cholesterol	12 weeks	Change is defined as Post-Baseline minus Baseline
Change From Baseline in Fasting LDL Cholesterol	12 weeks	Change is defined as Post-Baseline minus Baseline
Total Cholesterol Change From Baseline	12 weeks	Change is defined as Post-Baseline minus Baseline
Triglyceride Change From Baseline	12 weeks	Change is defined as Post-Baseline minus Baseline

Trial Locations

Locations (2)

University of Miami, Diabetes Unit D-1; 🇺🇸 Miami, Florida, United States

International Diabetes Center; 🇺🇸 Minneapolis, Minnesota, United States